September 18, 2017 Bio/Pharma/CRO PR/Corporate

Phase III data showed that Venclexta/Venclyxto plus MabThera/Rituxan helped people with previously treated chronic lymphocytic leukaemia live longer without their disease worsening compared to bendamustine plus MabThera/Rituxan

Basel, 18 September 2017 Phase III data showed that Venclexta/Venclyxto plus MabThera/Rituxan helped people with previously treated chronic lymphocytic leukaemia live longer without their disease worsening compared to bendamustine plus MabThera/Rituxan Data from pivotal phase III study will be submitted to health authorities and presented at an upcoming medical meeting Roche (SIX: RO, ROG; OTCQX:... Read more

September 18, 2017 Bio/Pharma/CRO PR/Corporate

Phase III data showed that Venclexta/Venclyxto plus MabThera/Rituxan helped people with previously treated chronic lymphocytic leukaemia live longer without their disease worsening compared to bendamustine plus MabThera/Rituxan

Basel, 18 September 2017 Phase III data showed that Venclexta/Venclyxto plus MabThera/Rituxan helped people with previously treated chronic lymphocytic leukaemia live longer without their disease worsening compared to bendamustine plus MabThera/Rituxan Data from pivotal phase III study will be submitted to health authorities and presented at an upcoming medical meeting Roche (SIX: RO, ROG; OTCQX:... Read more

September 15, 2017 Clinical Research/Diagn. Microscopy

TECENTRIQ GO29695 (NCT02431208) and BO29562 (NCT02631577) partial clinical hold reactive statement

Basel, 15 September 2017 TECENTRIQ GO29695 (NCT02431208) and BO29562 (NCT02631577) partial clinical hold reactive statement Roche (SIX: RO, ROG; OTCQX: RHHBY): Based on emerging safety data from clinical trials evaluating pembrolizumab in combination with either lenalidomide or pomalidomide in multiple myeloma, the FDA has requested that a Phase Ib and a Phase Ib/II TECENTRIQ study... Read more

September 13, 2017 Licensing, IP, and Legal PR/Corporate

Results of a six-month study combining Roche’s Esbriet with nintedanib in patients with IPF presented at ERS

Basel, 13 September 2017 Results of a six-month study combining Roche’s Esbriet with nintedanib in patients with IPF presented at ERS New study combining Esbriet (pirfenidone) and nintedanib showing similar safety profile for the combination treatment to that expected for each treatment alone A second, retrospective, post-hoc, analysis suggests that treatment with Esbriet may be... Read more

September 13, 2017 Licensing, IP, and Legal PR/Corporate

Results of a six-month study combining Roche’s Esbriet with nintedanib in patients with IPF presented at ERS

Basel, 13 September 2017 Results of a six-month study combining Roche’s Esbriet with nintedanib in patients with IPF presented at ERS New study combining Esbriet (pirfenidone) and nintedanib showing similar safety profile for the combination treatment to that expected for each treatment alone A second, retrospective, post-hoc, analysis suggests that treatment with Esbriet may be... Read more

September 11, 2017 Bio/Pharma/CRO

Roche announces phase III study results of Zelboraf for adjuvant treatment of BRAF V600 mutation-positive melanoma

Basel, 11 September 2017 Roche announces phase III study results of Zelboraf for adjuvant treatment of BRAF V600 mutation-positive melanoma Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced data for the phase III BRIM8 study, which was designed to investigate the efficacy and safety of Zelboraf® (vemurafenib) in the adjuvant (after surgery) treatment of people... Read more

September 8, 2017 Bio/Pharma/CRO

Roche provides update on first lampalizumab phase III study for geographic atrophy, an advanced form of age-related macular degeneration

Basel, 08 September 2017 Roche provides update on first lampalizumab phase III study for geographic atrophy, an advanced form of age-related macular degeneration Spectri study did not meet its primary endpoint of reducing mean change in geographic atrophy lesion area in patients treated with lampalizumab compared with sham treatment Safety profile was in line with... Read more

September 8, 2017 Clinical Research/Diagn.

Roche announces progress in biomarker science in cancer immunotherapy at the European Society for Medical Oncology Congress

Basel, 08 September 2017 Roche announces progress in biomarker science in cancer immunotherapy at the European Society for Medical Oncology Congress First data on new blood-based assay for measuring tumour mutational burden Two prospective studies underway to assess the potential of tumour mutational burden to predict response to certain cancer immunotherapies Roche (SIX: RO, ROG;... Read more

September 6, 2017 Uncategorized

Roche ranked again the most sustainable healthcare company in the Dow Jones Sustainability Indices

Basel, 07 September 2017 Roche ranked again the most sustainable healthcare company in the Dow Jones Sustainability Indices Roche recognised as a sustainability leader for the ninth year in a row Sustainability is an integral part of Roche’s business strategy The company performed particularly well in the categories addressing the burden of healthcare costs, ethical... Read more

September 6, 2017 Bio/Pharma/CRO Clinical Research/Diagn. PR/Corporate

Roche presents data from global phase III study showing significant clinical benefit of Alecensa (alectinib) in later-line advanced ALK-positive lung cancer

Basel, 06 September 2017 Roche presents data from global phase III study showing significant clinical benefit of Alecensa (alectinib) in later-line advanced ALK-positive lung cancer ALUR study shows 85% reduction in risk of disease worsening or death versus chemotherapy in patients with advanced ALK-positive NSCLC who had progressed on chemotherapy and crizotinib Roche (SIX: RO,... Read more